Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celera Group

http://www.celera.com

Latest From Celera Group

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.

Deal Watch Business Strategies

Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches

US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.

Biosimilars Launches

South Korea Sees Pharma Leadership Transition

Leadership succession is proceeding within South Korean pharmaceutical corporations such as Daiichi Sankyo Korea, Astellas Pharma Korea, Kyowa Kirin Korea as well as MSD Korea.

Asia Pacific South Korea

Alvotech Lauds Development, Manufacturing Platform As Ustekinumab Wins US Approval

Alvotech’s high confidence for FDA approval for its Stelara biosimilar has been justified, as the Icelandic firm announced only the second US approval for a rival to J&J’s Stelara powerhouse brand, ahead of market formation in 2025.

Approvals Biosimilars
See All

Company Information

UsernamePublicRestriction

Register